TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02125175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT boost Radiotherapy
Study: NCT00108225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LoBag Diet - test phase
Description: A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LoBAG Diet - control phase
Description: A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
Study: NCT04074642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurosurgery
Description: adenoma removal
Study: NCT04328844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-244
Description: IOA-244 will be administered orally once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab will be administered IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab will be administered IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab will be administered IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Injection
Description: Avelumab will be administered IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV every 3 weeks
Study: NCT00708383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% SSS embryo culture medium protein supplementation
Description: 10% SSS in addition to the 0.5% HSA already in the culture medium.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% HSA embryo culture medium protein supplementation
Description: 0.5% HSA in the culture medium
Study: NCT01292512

Intervention type: OTHER
Group type: OTHER
Intervention: Prognostic screening for complicated grief
Description: Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prognostic screening for complicated grief
Description: Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
Study: NCT02100865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen from cylinders
Study: NCT00624871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid (vitamin C)
Description: IV, 100 mg/kg/day, every day, for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03782857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
Study: NCT05305521

Intervention type: PROCEDURE
Intervention: transcrestal sinus floor elevation
Description: Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.

Intervention type: PROCEDURE
Intervention: Implant placement
Description: Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament
Study: NCT04155983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
Study: NCT01113710

Intervention type: DRUG
Intervention: Neupro®
Description: Neupro® is the exposure/intervention of interest in this non-interventional study.
Study: NCT03090334

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: De-escalation
Description: Antifungal therapy will be stopped according with BG results
Study: NCT03136783

Intervention type: OTHER
Group type: OTHER
Intervention: Development of the most specific physiologically relevant experimental patient models
Description: Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
Study: NCT03086239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Intravenous
Study: NCT02431676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach Directed Behavioral Weight Loss
Description: Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-control weight loss
Study: NCT04013672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks
Study: NCT04328844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice a day (BD)
Study: NCT04013672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SurVaxM
Description: 500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SurVaxM
Description: 500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
Study: NCT01737177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine, Lenalidomide, Rituximab
Description: INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days
Study: NCT03575429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement Intervention
Description: Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement + Coaching Intervention
Description: ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
Study: NCT02754791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steripath
Description: A device that diverts the first 2 ml of blood drawn in order to reduce contamination

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soluprep
Description: Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
Study: NCT02447484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mujer Segura Siempre
Description: Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Message Texts
Description: Participants receive generic health-promotion text messages twice a day, five days per week.
Study: NCT04536233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs Derived Pleiotropic Factors
Description: The pleiotropic factor derived from mesenchymal stem cells was injected on the wound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: The physiological saline was injected on the wound
Study: NCT00717210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal radiotherapy
Description: 54-60 Gy in 28-30 fractions over 6-7 weeks
Study: NCT00087191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin lutetium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02600169

Intervention type: DRUG
Intervention: Pemprolizumab
Description: All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
Study: NCT04574310

Intervention type: OTHER
Intervention: Collect retrospectively data on embryo implantation rate
Description: Collect retrospectively data on embryo implantation rate

Intervention type: OTHER
Intervention: Collect retrospectively data on embryo implantation rate
Description: Collect retrospectively data on embryo implantation rate
Study: NCT03015142

Intervention type: DEVICE
Intervention: New image-guidance software
Description: Patients in this group had spine surgery with new image-guidance software application
Study: NCT03103009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
Study: NCT03592381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Expansion by ossedensification
Description: Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge expansion by ridge splitting
Description: using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
Study: NCT04013672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Description: 1 ml per dose dosed every two weeks for 4 doses and then every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Description: 1 ml per dose dosed every two weeks for 4 doses and then every 3 months
Study: NCT01142297

Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant and modified dental implant
Description: standard SLA surface and chemically modified surface
Study: NCT03229031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES135
Description: ES135 will be administered via intrathecal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ES135
Description: ES135 will be administered via intrathecal
Study: NCT00813371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Pressure Release Ventilation
Description: Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARDSnet protocol
Description: ARDSnet protocol
Study: NCT03124485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty
Description: An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
Study: NCT02100449

Intervention type: OTHER
Group type: OTHER
Intervention: Lung ultrasound and Doppler (Day 0)
Description: In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
Study: NCT02179892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Extended-Release Liposome Injection (Exparel)
Description: 266mg/30mL of Exparel will be injected via unilateral TAP block
Study: NCT02100449

Intervention type: OTHER
Group type: OTHER
Intervention: Lung ultrasound and Doppler (Day 0)
Description: In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
Study: NCT01283633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
Study: NCT02023632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Similar-Age-Same-Gender (SASG)
Description: The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Similar-Age-Mixed-Gender (SAMG)
Description: The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mixed-Age-Mixed-Gender (MASG)
Description: The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
Study: NCT02286518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule
Study: NCT02179892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Dexamethasone Injection
Description: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
Study: NCT04195464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: Sham Dry needling use a non-penetrating acupuncture needle